Your browser doesn't support javascript.
Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.
Laurén, Ida; Havervall, Sebastian; Ng, Henry; Lord, Martin; Pettke, Aleksandra; Greilert-Norin, Nina; Gabrielsson, Lena; Chourlia, Aikaterini; Amoêdo-Leite, Catarina; Josyula, Vijay S; Eltahir, Mohamed; Kerzeli, Iliana; Falk, August J; Hober, Jonathan; Christ, Wanda; Wiberg, Anna; Hedhammar, My; Tegel, Hanna; Burman, Joachim; Xu, Feifei; Pin, Elisa; Månberg, Anna; Klingström, Jonas; Christoffersson, Gustaf; Hober, Sophia; Nilsson, Peter; Philipson, Mia; Dönnes, Pierre; Lindsay, Robin; Thålin, Charlotte; Mangsbo, Sara.
  • Laurén I; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Havervall S; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
  • Ng H; Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Lord M; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Pettke A; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Greilert-Norin N; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
  • Gabrielsson L; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
  • Chourlia A; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Amoêdo-Leite C; Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Josyula VS; Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Eltahir M; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Kerzeli I; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
  • Falk AJ; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Hober J; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden.
  • Christ W; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
  • Wiberg A; Department of Medicine Huddinge, Karolinska Institute, Centre for Infectious Medicine, Stockholm, Sweden.
  • Hedhammar M; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
  • Tegel H; Division of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Burman J; Division of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Xu F; Department of Neuroscience, Uppsala University, Uppsala, Sweden.
  • Pin E; Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Månberg A; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden.
  • Klingström J; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden.
  • Christoffersson G; Department of Medicine Huddinge, Karolinska Institute, Centre for Infectious Medicine, Stockholm, Sweden.
  • Hober S; Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Nilsson P; Division of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Philipson M; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden.
  • Dönnes P; Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Lindsay R; SciCross AB, Skövde, Sweden.
  • Thålin C; Department of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Mangsbo S; Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Immun Inflamm Dis ; 10(4): e595, 2022 04.
Article in English | MEDLINE | ID: covidwho-1739165
ABSTRACT

BACKGROUND:

Cellular immune memory responses post coronavirus disease 2019 (COVID-19) have been difficult to assess due to the risks of contaminating the immune response readout with memory responses stemming from previous exposure to endemic coronaviruses. The work herein presents a large-scale long-term follow-up study investigating the correlation between symptomology and cellular immune responses four to five months post seroconversion based on a unique severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific peptide pool that contains no overlapping peptides with endemic human coronaviruses.

METHODS:

Peptide stimulated memory T cell responses were assessed with dual interferon-gamma (IFNγ) and interleukin (IL)-2 Fluorospot. Serological analyses were performed using a multiplex antigen bead array.

RESULTS:

Our work demonstrates that long-term SARS-CoV-2-specific memory T cell responses feature dual IFNγ and IL-2 responses, whereas cross-reactive memory T cell responses primarily generate IFNγ in response to SARS-CoV-2 peptide stimulation. T cell responses correlated to long-term humoral immune responses. Disease severity as well as specific COVID-19 symptoms correlated with the magnitude of the SARS-CoV-2-specific memory T cell response four to five months post seroconversion.

CONCLUSION:

Using a large cohort and a SARS-CoV-2-specific peptide pool we were able to substantiate that initial disease severity and symptoms correlate with the magnitude of the SARS-CoV-2-specific memory T cell responses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Immun Inflamm Dis Year: 2022 Document Type: Article Affiliation country: Iid3.595

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Immun Inflamm Dis Year: 2022 Document Type: Article Affiliation country: Iid3.595